Bharat Biotech submits Clinical Trial data to CDSCO for Covaxin in children

If approved, Covaxin will be the first C-19 vaccine that can be administered to children in India.

93

Last Updated on October 9, 2021 by The Health Master

HYDERABAD: Bharat Biotech, which completed the Phase 2/3 trials of C-19 vaccine Covaxin for use in children under 18 years of age, has submitted the data to the Central Drugs Standard Control Organisation (CDSCO) for its verification and subsequent approval for Emergency Use Authorisation for the jab, company sources said on Wednesday.

Covaxin clinical trial data of 2-18 years age group has been submitted to CDSCO. This is feasible due to the safety of the manufacturing platform and empirical evidence from Phase 1,2 and 3 clinical trials in adults,” sources told.

Chairman and Managing Director of Bharat Biotech International Ltd, Krishna Ella, had said on September 21 that the Paediatric Covaxin completed phase 2/3 trials with about 1,000 subjects and the data analysis was going on.

As part of the Phase II/III trial, the two-dose Covaxin was administered with 28 days apart.

“We will be submitting the data (to the regulator) by next week,” he had said.

He also had said that Phase 2 trials of intranasal vaccine to prevent C-19 were going on and expected to be over in October.

If approved, Covaxin will be the first C-19 vaccine that can be administered to children in India.

Notifications: New Drugs, FDC, Clinical Trial

Other details about New Drugs, FDCs, Clinical trial

Covishield

Covaxin

Sputnik V

Modenra

NMC releases draft Post Graduate Medical Education Regulation 2021

FDA to launch prosecution against 77 Medical Stores

New Drugs, Cosmetics & Medical Devices bill should align with MDR…

Govt notifies amended Rules on Mfg of Ayurveda, Siddha and Unani…

NPPA releases draft of ceiling price calculation sheet for 2 drugs

CDSCO to start BA/BE studies registration process online from Oct 15

Latest Notifications regarding Pharmaceuticals

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner